Tobira Therapeutics Announces Date of 2016 Second Quarter Financial Results and CENTAUR Study Update Conference Call

SOUTH SAN FRANCISCO, Calif., Aug. 1, 2016 -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, will report financial results for the quarter ended June 30, 2016 after market close on Tuesday, August 9, 2016. The company will conduct a conference call and an audio webcast, with accompanying slides, at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.

Tobira CEO Laurent Fischer, M.D. and Chief Medical Officer Eric Lefebvre, M.D., will be joined by guest speaker Arun J. Sanyal, M.D., Charles Caravati Distinguished Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University to discuss cenicrivoc, the results from the CENTAUR study and the broader NASH landscape.

Date:	August 9, 2016
Time:	4:30 PM ET

Listen via Internet: http://ir.tobiratx.com/ 

Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=71384&k=54817826 

Toll-free:     1 (855) 638-8858
International: +1 (707) 294-1299
Access code:   59149594

A webcast replay will be available on the Tobira website for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 59149594.

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at www.tobiratx.com.

Tobira(R) is a registered trademark owned by Tobira Therapeutics, Inc.

(c)2016 Tobira Therapeutics, Inc. All Rights Reserved.

CONTACT: Tobira Investor & Media Contact
         Ian Clements, PhD
         +1 (650) 351-5013
         [email protected]

         BrewLIfe Media Contact
         Kelly Boothe
         +1 (415) 946-1076
         [email protected]